Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
نویسندگان
چکیده
D. Dias Carlson, and Murphy. Drafting of the manuscript: G. D. Dias Carlson. Critical revision of the manuscript for important intellectual content: J. A. Carlson, Murphy, and Rohwedder. Statistical analysis: J. A. Carlson and G. D. Dias Carlson. Obtained funding: J. A. Carlson. Administrative, technical, and material support: J. A. Carlson and Murphy. Study supervision: J. A. Carlson. Financial Disclosure: None reported. Funding/Support: This work was supported in part by clinical revenues and generous donors to the Divisions of Dermatology and Dermatopathology, Department of Pathology, Albany Medical College.
منابع مشابه
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
BACKGROUND Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis. OBJECTIVE Evaluate efficacy and safety of apremilast vs. placebo in biologic-naive patients with moderate-to-severe plaque psoriasis and safety of switching from etanercept to apremilast in a phase IIIb, randomized, double-blind, placebo-contro...
متن کاملScar sarcoidosis on 18F-FDG PET/CT
18F-labeled fluoro-2-deoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) is an important imaging modality in the clinical workup of patients with chronic inflammatory disorders which present quite often with a fever of unknown origin. Sarcoidosis is a multisystem chronic inflammatory disorder with a wide clinical spectrum that can involve different organs. The diagno...
متن کاملNew and emerging therapies in psoriasis.
This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab,...
متن کاملIdentification of Mycobacteria species in cutaneous lesions of Sarcoidosis by PCR-Restriction Ragment Length Polymorphism (PCR-RFLP) method
Background: Sarcoidosis is a granulomatous multisystem disease of unknown etiology. It has recently been tired to detect Mycobacteria genome in biopsy specimens of patients with sarcoidosis by Polymorphism chain reaction method. Objective: To detect and identify Mycobacteria species in cutaneous lesions of the patients with sarcoidosis by PCR-RFLP. Patients and methods: 20 patients with clinica...
متن کاملSafety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
BACKGROUND Apremilast, an oral phosphodiesterase-4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE To evaluate long-term efficacy and safety of apremilast in biologic-naive patients with moderate to severe plaque psoriasis and safety of switching from etanercept to apremilast in the phase 3b LIBERATE trial. METHODS Two hundred fifty patients wer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Archives of dermatology
دوره 148 2 شماره
صفحات -
تاریخ انتشار 2012